Tag: pan-mutant selective inhibitor
-
Novartis to acquire Synnovation program in up to $3 billion oncology deal
Novartis has agreed to acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics, in a deal worth up to $3 billion, strengthening the Swiss drugmaker’s push into precision oncology and next-generation breast cancer…